You folks may remember a minicap company called Synairgen being...

You folks may remember a minicap company called Synairgen being mentioned in these threads over the years as they were, apart from Biota, the only ones working in the rhinovirus space. Despite results of their Phase 2a trials on rhinovirus induced asthma attacks not being great, and using data trawling to get the result they wanted, they appear to have pulled off a great licensing deal given the particular circumstances.

$7.25M upfront and a total of $225M in milestones/funding. AstraZeneca is planning to do another Phase 2a trial next year. In terms of nearology, what does this mean for Vapendavir? One would be forgiven in asking why Biota is having trouble licensing Vap.



http://www.fiercebiotech.com/story/...opping-spree-232m-asthma-drug-deal/2014-06-12